Biliary Tract Neoplasms Immunotherapy
5 clinical trials · Condition
◉ Watch Biliary Tract Neoplasms Immunotherapy
| Record | Firm | Date |
|---|---|---|
| Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract Cancer (NCT07670273) | Peking Union Medical College Hospital | 2026-04-29 |
| Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract Cancer (NCT07704177) | Peking Union Medical College Hospital | 2026-04-15 |
| A Phase II Study of Adjuvant Durvalumab Combined With GEMOX/GC Chemotherapy Followed by Lenvatinib Versus Capecitabine in Biliary Tract Cancer. (NCT07679399) | Peking Union Medical College Hospital | 2025-06-01 |
| Toripalimab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer (NCT06362317) | Peking Union Medical College Hospital | 2024-03-06 |
| Pembrolizumab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer (NCT06230471) | Peking Union Medical College Hospital | 2023-01-09 |
Track Biliary Tract Neoplasms Immunotherapy automatically
Every clearance here is in the API, with alerts when new ones post.